Amos Adler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amos Adler has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
G. Avrahami
Schneider Children’s Medical Center of Israel
2 shared publicationsI. Levy
Schneider Children’s Medical Center of Israel
2 shared publicationsI. Yaniv
Schneider Children’s Medical Center of Israel
2 shared publicationsJ. Yacobovich
Schneider Children’s Medical Center of Israel
2 shared publicationsS. Fisher
Schneider Children’s Medical Center of Israel
2 shared publicationsZ. Samra
Rabin Medical Center
2 shared publications
Latest Publications
- 21 December 2006
- Published by Wiley in Acta Paediatrica
- Vol. 96 (3) , 428-431
Parent‐dependent barriers to varicella immunization in Israel: the importance of adequate information
Aim: To examine the parent‐dependent barriers to varicella immunization in Israel.Methods: Data were collected by questionnaire from parents of children aged 1 to 18 years who attended an outpatient paediatric centre in five cities in Israel from March to May 2003.Results: A total of 1474 parents completed the questionnaire. A history of chicken pox was reported in 850 children (57.8%), mostly (83%) between ages 1–6 years. Of the 624 children without a history of chicken pox, 213 (34.1%) were immunized against varicella. Immunization rates were significantly lower in families with lower parental education and in patients from cities with a lower socioeconomic ranking (p < 0.05). The main reasons for not being vaccinated (49%) were related to insufficient information about the vaccine itself and the vaccination process. These reasons were more common in families with lower parental education and from cities with lower socioeconomic ranking (p < 0.01). Other reasons included fear of adverse effects (12%) and waning immunity (6%), preference of natural illness over immunization (12%), and financial limitations (5%).Conclusions: Promoting parental knowledge about the varicella vaccine appears to be a key factor in improving the immunization rate, especially in families of lower education, and from cities with low socioeconomic ranking.
- 21 December 2006
- Published by Wiley in Acta Paediatrica
- Vol. 96 (3) , 428-431
Parent‐dependent barriers to varicella immunization in Israel: the importance of adequate information
Aim: To examine the parent‐dependent barriers to varicella immunization in Israel.Methods: Data were collected by questionnaire from parents of children aged 1 to 18 years who attended an outpatient paediatric centre in five cities in Israel from March to May 2003.Results: A total of 1474 parents completed the questionnaire. A history of chicken pox was reported in 850 children (57.8%), mostly (83%) between ages 1–6 years. Of the 624 children without a history of chicken pox, 213 (34.1%) were immunized against varicella. Immunization rates were significantly lower in families with lower parental education and in patients from cities with a lower socioeconomic ranking (p < 0.05). The main reasons for not being vaccinated (49%) were related to insufficient information about the vaccine itself and the vaccination process. These reasons were more common in families with lower parental education and from cities with lower socioeconomic ranking (p < 0.01). Other reasons included fear of adverse effects (12%) and waning immunity (6%), preference of natural illness over immunization (12%), and financial limitations (5%).Conclusions: Promoting parental knowledge about the varicella vaccine appears to be a key factor in improving the immunization rate, especially in families of lower education, and from cities with low socioeconomic ranking.
- Open Access
- 5 April 2006
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (4) , 254-256
Exserohilum: an emerging human pathogen
- 5 April 2006
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (4) , 254-256
Open AccessExserohilum: an emerging human pathogen
- 2 March 2006
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (4) , 247-253
Exserohilum: an emerging human pathogen
Exserohilum is a dematiaceous fungus that may cause a spectrum of diseases in humans, including skin and corneal infection, invasive disease, and allergic fungal sinusitis. The aim of this work is to describe two new cases of Exserohilum infection and to review the literature. The review yielded 33 cases of Exserohilum infection, of which 23 were reported since 1993. Most occurred in regions with hot climates, such as India, Israel, and the southern USA. Impaired immunity was present in the majority of patients with invasive and skin infections, whereas local trauma and atopy were the predisposing factors in those with corneal infections and allergic fungal sinusitis, respectively. Surgical debridement was the principal mode of therapy for allergic fungal sinusitis. Amphotericin B was the initial single antifungal agent used in all cases of invasive disease; the response rate was low but improved with the addition of triazole agents. Outcome appeared to be better than for other mold infections and depended mainly on the underlying diseases.
- 2 March 2006
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (4) , 247-253
Exserohilum: an emerging human pathogen
Exserohilum is a dematiaceous fungus that may cause a spectrum of diseases in humans, including skin and corneal infection, invasive disease, and allergic fungal sinusitis. The aim of this work is to describe two new cases of Exserohilum infection and to review the literature. The review yielded 33 cases of Exserohilum infection, of which 23 were reported since 1993. Most occurred in regions with hot climates, such as India, Israel, and the southern USA. Impaired immunity was present in the majority of patients with invasive and skin infections, whereas local trauma and atopy were the predisposing factors in those with corneal infections and allergic fungal sinusitis, respectively. Surgical debridement was the principal mode of therapy for allergic fungal sinusitis. Amphotericin B was the initial single antifungal agent used in all cases of invasive disease; the response rate was low but improved with the addition of triazole agents. Outcome appeared to be better than for other mold infections and depended mainly on the underlying diseases.